新型免疫分析法检测脑脊液p-tau T217鉴别阿尔茨海默病与其他痴呆
研究开发并验证了一种检测脑脊液p-tau T217的Simoa免疫分析法,在190名参与者(AD 77例、其他神经退行性疾病69例、健康对照44例)中评估其鉴别AD与其他痴呆及健康对照的能力。结果显示p-tau T217鉴别AD的准确性为90%,优于p-tau T181 ELISA的78%,且与健康对照的鉴别表现与p-tau T181相似。
要点
- p-tau T217鉴别AD与其他痴呆的准确性为90%,优于p-tau T181的78%。
- p-tau T217区分AD与健康对照的敏感性98%、特异性93%。
- p-tau T217与p-tau T181、总tau和β-淀粉样蛋白40强相关,与β-淀粉样蛋白42不相关。
核心结论
- p-tau T217的诊断准确性优于p-tau T181,有潜力作为临床评估中的AD诊断检测。
研究设计与样本
- 开发并验证了一种检测脑脊液p-tau T217的新型Simoa免疫分析法,共纳入来自3个队列的190名参与者,包括AD患者77例、其他神经退行性疾病患者69例和健康参与者44例。
主要发现
- p-tau T217( cutoff 242 pg/mL)鉴别AD的准确性为90%,阳性预测值78%,阴性预测值97%,敏感性93%,特异性88%。
- p-tau T181 ELISA( cutoff 52 pg/mL)的准确性为78%,阳性预测值58%,阴性预测值98%,特异性71%,敏感性97%。
- p-tau T217( cutoff 163 pg/mL)区分AD与年龄匹配健康对照的敏感性98%、特异性93%,p-tau T181 ELISA( cutoff 60 pg/mL)为敏感性96%、特异性86%。
- 在AD患者中,p-tau T217与p-tau T181、总tau和β-淀粉样蛋白40强相关,但与β-淀粉样蛋白42不相关。
临床怎么用
- 该新型p-tau T217免疫分析法有潜力作为临床评估中鉴别AD与其他痴呆及健康对照的诊断检测。
局限性
- 本研究提供的是Class III证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether tau phosphorylated at Thr217 (p-tau T217) assay in CSF can distinguish patients with Alzheimer disease (AD) from patients with other dementias and healthy controls. METHODS: We developed and validated a novel Simoa immunoassay to detect p-tau T217 in CSF. There was a total of 190 participants from 3 cohorts with AD (n = 77) and other neurodegenerative diseases (n = 69) as well as healthy participants (n = 44). RESULTS: The p-tau T217 assay (cutoff 242 pg/mL) identified patients with AD with accuracy of 90%, with 78% positive predictive value (PPV), 97% negative predictive value (NPV), 93% sensitivity, and 88% specificity, compared favorably with p-tau T181 ELISA (52 pg/mL), showing 78% accuracy, 58% PPV, 98% NPV, 71% specificity, and 97% sensitivity. The assay distinguished patients with AD from age-matched healthy controls (cutoff 163 pg/mL, 98% sensitivity, 93% specificity), similarly to p-tau T181 ELISA (cutoff 60 pg/mL, 96% sensitivity, 86% specificity). In patients with AD, we found a strong correlation between p-tau T217 and p-tau T181, total tau and β-amyloid 40, but not β-amyloid 42. CONCLUSIONS: This study demonstrates that p-tau T217 displayed better diagnostic accuracy than p-tau T181. The data suggest that the new p-tau T217 assay has potential as an AD diagnostic test in clinical evaluation. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that a CSF immunoassay for p-tau T217 distinguishes patients with AD from patients with other dementias and healthy controls.
引用
- Hanes J, Kovac A, Kvartsberg H, et al. Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology. 2020. PMID: 32973122. doi:10.1212/WNL.0000000000010814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。